NCT05831787 · ADVERSE EVENTS

Adverse events

COVID19 OutcomeS in Myeloma and the Impact of VaCcines · Source last updated 2026-05-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: Per protocol, in this observational study, adverse events were not monitored or assessed; therefore, there are no adverse event results to report over the 6 month study timeframe.
Other-event reporting threshold: 0%

Per protocol, adverse events were not prospectively or systematically collected or monitored/assessed as part of this decentralized observational study.

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Diagnosis of Multiple Myeloma and Currently Receiving Active Treatment for Any Phase of the Disease Diagnosis of multiple myeloma must meet the International Myeloma Working Group criteria. Patient Reported Outcomes: Patients will be asked to complete baseline, 30-day, and 6-month clinical and patient reported outcome health surveys.	0 / 0	0 / 0	0 / 0

Group identifiers: EG000: Diagnosis of Multiple Myeloma and Currently Receiving Active Treatment for Any Phase of the Disease

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Complete source fields

description

Per protocol, adverse events were not prospectively or systematically collected or monitored/assessed as part of this decentralized observational study.

event Groups

deaths Num Affected
0
deaths Num At Risk
0
description
Diagnosis of multiple myeloma must meet the International Myeloma Working Group criteria. Patient Reported Outcomes: Patients will be asked to complete baseline, 30-day, and 6-month clinical and patient reported outcome health surveys.
id
EG000
other Num Affected
0
other Num At Risk
0
serious Num Affected
0
serious Num At Risk
0
title
Diagnosis of Multiple Myeloma and Currently Receiving Active Treatment for Any Phase of the Disease

frequency Threshold

time Frame

Per protocol, in this observational study, adverse events were not monitored or assessed; therefore, there are no adverse event results to report over the 6 month study timeframe.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice